**Introduction:** This is a case of Mr O, who is a 62 year old gentleman with polyarticular, chronic, diuretic induced gout. He has a significant and debilitating cardiac history and is known to have intolerance to various urate lowering therapeutic agents (ULT) making management of his Gouty arthritis a real challenge in both primary and secondary care.

**Case description:** Mr O presented to our rheumatology clinic with an over 10 year history of recurrent, typical gouty flares affecting his metatarso-phalangeal joints, ankles and knees with a frequency of at least 10 attacks every year and persistently elevated urate levels (\>600 micromoles/L). This was despite optimal dietary and life style modifications as per guidelines. He has a background of dilated cardiomyopathy, significant heart failure and left ventricular thrombus with an ICD insitu. His medication includes long-term warfarin, bumatanide, spironolactone, bisoprolol and ramipril. Initially, he was treated with allopurinol which he was true intolerant to. Subsequently, sulfinpyrazone was commenced and discontinued due to interaction with warfarin and a labile INR. Unfortunately, second generation ULT, Febuxostat, was not an option due to the cardiac co-morbidity. He had been getting frequent flares which required hospital and primary care visits. His flares were managed with colchicine and the occasional short course of oral steroids. As we were unable to achieve tight control of his disease as per treat to target concept, he was referred to the regional gout expert. Mr O also had no prior history of renal stones. The expert's recommendation in these settings was a trial of a uricosuric drug such as sulfinpyrazone, benzbromarone or probenacid. Sulfinpyrazone could not be used due to interactions with warfarin and benzbromarone was also excluded due to elevated serum gamma-glutamyl transferase (GGT). Mr O was eventually started on Probenacid 500 mgs OD while renal function, liver function and urate levels were monitored regularly. On his next review, he showed clinical and biochemical improvement with serum urate levels dropping to 450 micromoles/L and stable renal and liver function. Probenacid dose was increased to 1 g/d to achieve recommended serum urate levels of \< 300 micromoles/L, but unfortunately, this precipitated a flare. Mr O stopped Probenacid thinking this was a reaction to the drug and subsequently, his symptoms worsened. On his next review in clinic, he was recounselled regarding the importance the increased cardiac risk with Gout, occurrence of flares on initiating or titrating ULT and the importance of self adherence to prescribed medication. His management was further complicated by the non availability of probenacid in the community pharmacy. This led to gaps in his treatment which were overcome by providing him with appropriate supplements through the hospital pharmacy. He is currently on regular probenacid with overall significant improvement.

**Discussion:** Though, this is a straight forward case of gout, this case posed several practical challenges in the primary and secondary care management. The following are some of the important highlights: 1. As gout in itself is a recognised cardiovascular risk factor, tight control of hyperuricaemia and gouty flares is crucial in this gentleman's overall management. 2. Multiple drug intolerance for urate lowering therapy should be carefully evaluated as true or partial intolerance. Clinicians should carefully evaluate symptoms before swapping medications. 3. Significant co-morbidities and drug interactions limit our choice of medications. 4. Drug availability at the hospital and community level is a continuing challenge, particularly for some of the infrequently used medications. 5. Drug adherence is key in managing chronic conditions particularly Gout as reflected in this case. Adequate counselling at primary and secondary care levels about ULT is essential.

**Key learning points:** This was an interesting case which highlighted several important learning points. 1. Drug intolerances to be carefully evaluated and addressed 2. Drug interactions of ULT particularly with polypharmacy should be assessed effectively by the treating clinicians. 3. Education and counselling patients regarding ULT to optimise adherence.
